What is FEMSelect?
FEMSelect is dedicated to addressing Pelvic Organ Prolapse (POP) through its FDA-cleared EnPlace procedure, a minimally invasive treatment designed for rapid patient recovery and return to daily activities. The company actively engages in patient and medical professional education, aiming to raise awareness about POP symptoms and management. By focusing on restoring quality of life, FEMSelect positions itself as a key innovator in women's health, offering advanced solutions for a condition that affects a significant demographic.
How much funding has FEMSelect raised?
FEMSelect has raised a total of $9M across 1 funding round:
Series B
$9M
Series B (2022): $9M with participation from New Age Ventures, MEDA Angels, Mid Atlantic Bio Angels, Triventures, and Robin Hood Ventures
Key Investors in FEMSelect
New Age Ventures
New Age Ventures is a globally active venture studio investing in diverse sectors including healthcare and digital health, focusing on pre-seed to Series B startups. They provide resources to exceptional teams throughout the venture lifecycle.
MEDA Angels
MEDA Angels is a healthcare investment firm founded by physicians and scientists, leveraging extensive networks to support portfolio companies in healthcare solutions that benefit a wide range of stakeholders.
Mid Atlantic Bio Angels
Mid Atlantic Bio Angels is an angel investor group dedicated to investing in new and emerging life science companies globally, offering funding and feedback sessions for entrepreneurs.
What's next for FEMSelect?
With the recent influx of enterprise-level capital, FEMSelect is poised for accelerated expansion and further refinement of its EnPlace treatment. This strategic financing is expected to fuel advancements in product development, enhance market penetration, and broaden the company's reach to a larger patient population. The company's focus on innovation and patient well-being, combined with strong backing, suggests a trajectory towards becoming a leader in the urogynecology and women's health sectors. Future initiatives will likely involve scaling operations and increasing access to their transformative treatment options.
See full FEMSelect company page
